Lexaria Bioscience Corp.
LEXXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLexaria Bioscience Corp. operates as a biotechnology company. The company carries a $23.4M market cap, placing it firmly in the micro-cap category. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.
Market Cap
$23.4M
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
-36.28
EPS (TTM)
$-5.86
EPS (Fwd)
$-0.39
ROE
-162.8%
ROA
-81.3%
Cash
$3.6M
Total Debt
$86,714
Free CF
-$4.7M
52W Change
-21.0%
Annual Financials
Cash vs Debt
Where LEXX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, LEXX finished 29.89% above its 150-day moving average ($10.17) and 21.30% above its 200-day moving average ($10.89). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LEXX overbought or oversold?
At the September 3, 2026 close, LEXX's RSI(14) was 73.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.6M in cash comfortably exceeding the $87K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$4.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -162.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $255K (2022) to $706K (2025), reflecting a 176% increase over the period.
LEXX's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LEXX.